NCT07145073|Recruiting
Loading search results
Sponsor study identifier
interventional
188
1 country
1
Study Start
January 26, 2026
Actual (reported)Primary Completion
December 31, 2027
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Study Completion
December 31, 2028
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
The goal of this study is to see whether repeated transcranial alternating current stimulation can activate impaired retinal ganglion cells and improve both structural and functional outcomes in patients with glaucoma.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
December 31, 2028
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
August 11, 2025
Actual (reported)August 28, 2025
Actual (reported)January 26, 2026
Actual (reported)December 31, 2027
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
December 31, 2028
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Change in visual field mean deviation (MD) from baseline to post-treatment
Visual field testing will be performed with the Humphrey field analyzer
From treatment initiation to 26 days after treatment initiation
Change in visual field mean deviation (MD) from baseline to post-treatment
From treatment initiation to 12 days after treatment initiation
Change in visual field mean deviation (MD) from baseline to post-treatment
From treatment initiation to 19 days after treatment initiation
Change in visual field mean deviation (MD) from baseline to post-treatment
From treatment initiation to 166 days after treatment initiation
Change in sensitivity at each of the 52 test points in the 24-2 visual field from baseline to post-treatment
From treatment initiation to 26 days after treatment initiation
Change in targeted mean deviation from baseline to post-treatment
From treatment initiation to 12 days after treatment initiation
Participants will receive 10 days of repeated transcranial alternating current stimulation in hospital.
Participants will receive 10 days of repeated transcranial alternating current stimulation treatment (no active stimulation) in hospital.
Experimental：Participants will receive 10 days of repeated transcranial alternating current stimulation treatment in hospital.
Sham Comparator：Participants will receive 10 days of repeated transcranial alternating current stimulation treatment (no active stimulation) in hospital.
National Taiwan University Hospital
Taipei, Hawaii, 100, Taiwan
First Submitted
August 11, 2025
First Posted
August 28, 2025
Study Start
January 26, 2026
Actual (reported)Primary Completion
December 31, 2027
EstimatedCross-modal Neuromodulation to Improve Balance and Cognition in Older Adults With Glaucoma: A Randomized Trial of Cerebellar Transcranial Electrical Stimulation
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
Contact the study team to confirm eligibility.
Planned date reported by the registry; this milestone is not confirmed as achieved.
Study Completion
December 31, 2028
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Last Updated
January 30, 2026
Record last verified: 2025-08
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: